8 research outputs found

    Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens

    Get PDF
    Monocyte-derived Dendritic cells (DCs) have successfully been employed to induce immune responses against tumor-associated antigens in patients with various cancer entities. However, objective clinical responses have only been achieved in a minority of patients. Additionally, generation of GMP-compliant DCs requires time- and labor-intensive cell differentiation. In contrast, Blood DCs (BDCs) require only minimal ex vivo handling, as differentiation occurs in vivo resulting in potentially better functional capacities and survival. We aimed to identify a protocol for optimal in vitro activation of BDCs including the three subsets pDCs, cDC1s, and cDC2s. We evaluated several TLR ligand combinations and demonstrated that polyinosinic:polycytidylic acid poly(I:C) and R848, ligands for TLR3 and TLR7/8, respectively, constituted the optimal combination for inducing a positive co-stimulatory profile in all BDC subsets. In addition, TLR3 and TLR7/8 activation led to high secretion of IFN-α and IL-12p70. Simultaneous as opposed to separate tailored activation of pDCs and cDCs increased immunostimulatory capacities, suggesting that BDC subsets engage in synergistic cross-talk during activation. Stimulation of BDCs with this protocol resulted in enhanced migration, high NK-cell activation, and potent antigen-specific T-cell induction.We conclude that simultaneous activation of all BDC subsets with a combination of R848 + poly(I:C) generates highly immunostimulatory DCs. These results support further investigation and clinical testing, as standalone or in conjunction with other immunotherapeutic strategies including adoptive T-cell transfer and checkpoint inhibition

    Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy

    Get PDF
    The emergence of drug resistance in M. tuberculosis undermines the efficacy of tuberculosis (TB) treatment in individuals and of TB control programs in populations. Multiple drug resistance is often attributed to sequential functional monotherapy, and standard initial treatment regimens have therefore been designed to include simultaneous use of four different antibiotics. Despite the widespread use of combination therapy, highly resistant M. tb strains have emerged in many settings. Here we use a stochastic birth-death model to estimate the probability of the emergence of multidrug resistance during the growth of a population of initially drug sensitive TB bacilli within an infected host. We find that the probability of the emergence of resistance to the two principal anti-TB drugs before initiation of therapy ranges from 10−5 to 10−4; while rare, this is several orders of magnitude higher than previous estimates. This finding suggests that multidrug resistant M. tb may not be an entirely “man-made” phenomenon and may help explain how highly drug resistant forms of TB have independently emerged in many settings

    Influences on Human Internal Exposure to Environmental Platinum.

    No full text
    Abstract not availableJRC.H-Institute for environment and sustainability (Ispra

    Secondary DEHP-Metabolites and Human Semen Parameters

    No full text
    There is scientific and public concern about phthalates, that are associated with reproductive toxicity in laboratory animals and are hormonally active. The general population is exposed to phthalates through nutrition, consumer products and medical devices. The present study explored whether internal phthalate exposure can be related to parameters of semen quality (i.e. concentration, motility and morphology) in men.JRC.H.4-Transport and air qualit

    Zusammenhänge zwischen DEHP-Sekundärmetaboliten und Spermienbefunden bei Patienten einer andrologischen Ambulanz

    No full text
    Phthalate finden sich als Weichmacher in einer Vielzahl von PVC-Produkten, medizinischen Produkten, aber auch Körperpflegemitteln. Insbesondere Diethylhexylphthalat (DEHP, jährliche Produktion von ca. 2 Millionen Tonnen weltweit) zeigte im Tierversuch entwicklungs- und reproduktionstoxische Effekte. Daher werden entsprechende Auswirkungen auch beim Menschen vermutet. Zur kontaminationsfreien Expositionsbestimmung werden als spezifische Stoffwechselprodukte der Phthalate Metabolite des DEHP und anderer Phthalate herangezogen, die ausschließlich im menschlichen Körper entstehen. Ziele der vorliegenden Auswertung waren es, die Wiederholbarkeit der so gemessenen inneren Phthalatexposition sowie ihre mögliche Assoziationen zu Spermienbefunden zu untersuchen.JRC.G.2-Support to external securit

    Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

    Get PDF
    Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88−1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73−2.38; p = 0.44). Grade 3−4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed
    corecore